文献速递血栓与止血

免疫介导性血栓性血小板减少性紫癜的长期复发风险及抗CD20治疗的作用

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy.
PubMed 文献 · Blood · 2023-01-01

该研究回顾性分析了英国443例随访超过3年的免疫介导性血栓性血小板减少性紫癜(iTTP)患者,5年随访复发率为40%。黑加勒比族裔增加复发风险,约6%患者早期复发且后续频繁复发。近60%复发为ADAMTS13复发,抗CD20治疗使96%的ADAMTS13复发患者ADAMTS13活性升至>20%。

要点

  • iTTP患者5年随访复发率为40%,10年随访时急性期是否使用利妥昔单抗对复发率无差异(P = .39)。
  • 黑加勒比族裔增加英国人群iTTP疾病复发风险,约6%患者早期复发且平均1.7年内频繁复发。
  • 近60%复发为ADAMTS13复发,抗CD20治疗使96%患者ADAMTS13活性>20%,且后续治疗无反应丧失。

核心结论

  • iTTP患者长期复发风险显著,5年随访复发率为40%。
  • 黑加勒比族裔增加英国人群iTTP疾病复发风险。
  • 抗CD20治疗对ADAMTS13复发有效,96%患者ADAMTS13活性升至>20%,且后续治疗无反应丧失。

研究设计与样本

  • 回顾性研究,纳入英国443例随访超过3年的iTTP患者,研究期超过10年。

主要发现

  • 5年随访复发率为40%。
  • 10年随访时,急性期是否使用利妥昔单抗对复发率无差异(P = .39)。
  • 黑加勒比族裔增加英国人群iTTP疾病复发风险。
  • 约6%患者早期复发且后续频繁复发,该亚组平均复发时间为1.7年。
  • 近60%复发为ADAMTS13复发(ADAMTS13活性<20%无血小板减少),后续治疗降低进展为临床复发的风险。

关键数值与推荐

  • 研究后期诊断的iTTP患者临床复发率较低(22.6% vs 11.1%,P = .0004),与规律监测和抢先利妥昔单抗治疗的出现相关。
  • ADAMTS13复发患者中96%对抗CD20治疗有反应,达到ADAMTS13活性>20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disease relapse is recognized as a risk in immune-mediated thrombotic thrombocytopenic purpura (iTTP) after treatment of the acute presenting episode. Identification of patients at risk of relapse and its patterns are yet to be clearly established. We reviewed patients with iTTP having had >3 years of follow-up over 10 years in the United Kingdom to identify patient characteristics for relapse, assess relapse rates and patterns, and response to anti-CD20 therapy in those with a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) relapses (ADAMTS13 activity of <20% without thrombocytopenia). We identified 443 patients demonstrating relapse rates of 40% at 5-year follow-up. At 10-year follow-up, no difference in relapse was observed irrespective of whether rituximab was used at acute presentation (P = .39). Black Caribbean ethnicity increased the risk of disease relapse in the British population. There was a distinct population of patients (6%) that relapsed early with subsequent frequent relapses occurring on average within 2 years (average time to relapse in subgroup, 1.7 years). Overall, nearly 60% of relapses described were ADAMTS13 relapses, with subsequent treatment reducing the risk of progression to clinical relapses. We demonstrate that iTTP diagnosed in the latter part of the study period had lower rates of clinical relapses (22.6% vs 11.1%, P = .0004) with the advent of regular monitoring and preemptive rituximab. In ADAMTS13 relapses, 96% responded to anti-CD20 therapy, achieving ADAMTS13 activity of >20%. Anti-CD20 therapy was demonstrated to be an effective long-term treatment regardless of relapse pattern and there was no loss of this treatment response after subsequent treatment episodes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Doyle AJ, Stubbs MJ, Dutt T, et al. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Blood. 2023. PMID: 36322971. doi:10.1182/blood.2022017023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。